Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 2
2013 1
2015 1
2016 1
2017 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical drug development for childhood cancer.
Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AD. Moreno L, et al. Expert Opin Drug Discov. 2011 Jan;6(1):49-64. doi: 10.1517/17460441.2011.537652. Epub 2010 Nov 24. Expert Opin Drug Discov. 2011. PMID: 22646826
Novel therapies for children with acute myeloid leukaemia.
Moore AS, Kearns PR, Knapper S, Pearson AD, Zwaan CM. Moore AS, et al. Leukemia. 2013 Jul;27(7):1451-60. doi: 10.1038/leu.2013.106. Epub 2013 Apr 8. Leukemia. 2013. PMID: 23563239 Free article. Review.
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
Moore AS, Faisal A, Mak GWY, Miraki-Moud F, Bavetsias V, Valenti M, Box G, Hallsworth A, de Haven Brandon A, Xavier CPR, Stronge R, Pearson ADJ, Blagg J, Raynaud FI, Chopra R, Eccles SA, Taussig DC, Linardopoulos S. Moore AS, et al. Blood Adv. 2020 Apr 14;4(7):1478-1491. doi: 10.1182/bloodadvances.2019000986. Blood Adv. 2020. PMID: 32282883 Free PMC article.
Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas.
Carceller F, Jerome NP, Miyazaki K, Collins DJ, Orton MR, d'Arcy JA, Wallace T, Moreno L, Pearson AD, Zacharoulis S, Leach MO, Marshall LV, Koh DM. Carceller F, et al. Pediatr Blood Cancer. 2017 Feb;64(2):279-283. doi: 10.1002/pbc.26216. Epub 2016 Sep 12. Pediatr Blood Cancer. 2017. PMID: 27615273
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J. Bavetsias V, et al. J Med Chem. 2012 Oct 25;55(20):8721-34. doi: 10.1021/jm300952s. Epub 2012 Oct 8. J Med Chem. 2012. PMID: 23043539 Free PMC article.
Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study.
Miyazaki K, Jerome NP, Collins DJ, Orton MR, d'Arcy JA, Wallace T, Moreno L, Pearson AD, Marshall LV, Carceller F, Leach MO, Zacharoulis S, Koh DM. Miyazaki K, et al. Eur Radiol. 2015 Sep;25(9):2641-50. doi: 10.1007/s00330-015-3666-7. Epub 2015 Mar 15. Eur Radiol. 2015. PMID: 25773937 Free PMC article.
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S. Moore AS, et al. Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22. Leukemia. 2012. PMID: 22354205 Free PMC article.